News & Updates

Show Multimedia Only

Is 3-month DAPT noninferior to 1-year strategy in CABG patients?

21 May 2026 by

Treatment with dual antiplatelet therapy (DAPT) for 3 months is as good as the 12-month DAPT strategy in saphenous vein graft (SVG) occlusion but is more efficacious in reducing the risk of bleeding among patients undergoing elective coronary artery bypass grafting (CABG), a study has shown.

Is 3-month DAPT noninferior to 1-year strategy in CABG patients?

21 May 2026

Hypercholesterolemia does not worsen cognitive decline in arterial hypertension

21 May 2026

The presence of hypercholesterolemia shows no negative impact on cognitive function among individuals with hypertension, reports a study.

Hypercholesterolemia does not worsen cognitive decline in arterial hypertension

21 May 2026

Tegoprazan TRIUMpHs as PPI alternative for erosive esophagitis, heartburn

21 May 2026 by

Results from the phase III TRIUMpH-EE study demonstrate the superiority of the novel potassium-competitive acid blocker (P-CAB) tegoprazan over the proton pump inhibitor (PPI) lansoprazole in providing faster healing of erosive esophagitis (EE) and heartburn relief.

Tegoprazan TRIUMpHs as PPI alternative for erosive esophagitis, heartburn

21 May 2026

Methylphenidate may be safely used in patients with MDD

21 May 2026

Use of methylphenidate in adult patients with major depressive disorder (MDD) appears to be safe, being associated with reduced hospitalization or emergency visits without increasing the risk of suicidality, mania, or recurrence, according to a retrospective study.

Methylphenidate may be safely used in patients with MDD

21 May 2026

Gedatolisib-based regimens boost PFS in HR+/HER2– PIK3CA-WT ABC

21 May 2026 by

Treatment with gedatolisib plus fulvestrant, with or without palbociclib, significantly improves progression-free survival (PFS) in patients with HR+/HER2– PIK3CA wild-type (WT) advanced breast cancer (ABC) compared with fulvestrant alone, according to the VIKTORIA-1 trial presented at ESMO Breast Cancer 2026.

Gedatolisib-based regimens boost PFS in HR+/HER2– PIK3CA-WT ABC

21 May 2026

Aspirin mitigates preterm birth risk linked to heat exposure

20 May 2026

Initiating low-dose aspirin early in pregnancy may reduce the risk of preterm birth associated with heat exposure among nulliparous women, according to a study.

Aspirin mitigates preterm birth risk linked to heat exposure

20 May 2026

Response-adapted chemo-free adjuvant treatment feasible in low-risk HER2+ early breast cancer

20 May 2026 by

A neoadjuvant pathologic complete response-adapted de-escalation strategy to omit chemotherapy in the adjuvant setting is clinically feasible and helps preserve health-related quality of life in highly selected patients with low-risk HER2-positive early breast cancer, according to the phase II PHERGain-2 trial.

Response-adapted chemo-free adjuvant treatment feasible in low-risk HER2+ early breast cancer

20 May 2026

BP shows linear relationship with cardiovascular, renal outcomes in T2D

20 May 2026

Blood pressure (BP) demonstrates a linear or monotonic association with most cardiovascular and renal outcomes in individuals with type 2 diabetes (T2D), reports a study.